AGL Investor Deadline Approaching as Securities Class Action Deadline Nears March 2, 2026

New York, NY – Investors in agilon health, Inc. (NYSE: AGL) are being reminded that a critical legal deadline is fast approaching. National securities law firm Faruqi & Faruqi, LLP has issued a renewed alert to shareholders who suffered losses in agilon health, Inc. (“agilon health” or the “Company”), informing them of the March 2, 2026 deadline to seek appointment as lead plaintiff in a pending federal securities class action lawsuit.

The lawsuit alleges that agilon health and certain of its executives violated federal securities laws by making materially false and misleading statements and failing to disclose critical information to investors during the relevant class period. As the deadline draws near, affected investors are urged to review their legal rights and consider their options.

Overview of the Securities Class Action

The class action lawsuit was filed on behalf of investors who purchased or otherwise acquired agilon health securities during the specified class period. According to the complaint, the defendants allegedly misrepresented the Company’s financial health, operational stability, and business prospects, thereby artificially inflating the stock price.

When the truth allegedly emerged, agilon health’s stock price experienced significant declines, causing substantial losses for shareholders. The complaint claims that investors were harmed as a direct result of the Company’s purported misstatements and omissions.

Key Allegations in the Complaint

The lawsuit asserts that agilon health and certain senior executives:

• Made false or misleading statements regarding the Company’s financial performance and revenue growth;
• Failed to disclose material weaknesses in internal controls and operational risks;
• Provided overly optimistic guidance without a reasonable basis;
• Concealed information about cost pressures and reimbursement challenges impacting profitability.

These alleged actions, according to the complaint, violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

Who Is Eligible to Participate?

Investors who purchased or otherwise acquired agilon health securities during the defined class period and suffered financial losses may be eligible to participate in the lawsuit. Participation does not require investors to serve as lead plaintiff. However, those wishing to seek the role of lead plaintiff must file a motion with the Court by March 2, 2026.

The lead plaintiff acts on behalf of all class members and plays an important role in directing the litigation. The Court typically appoints the investor or group of investors with the largest financial interest in the case who also meets certain legal requirements.

Important Deadline: March 2, 2026

The March 2, 2026 deadline is a critical date for investors seeking to serve as lead plaintiff. Failing to file a motion by this date may result in forfeiting the opportunity to assume that leadership position, though investors may still remain part of the class if it is certified.

Faruqi & Faruqi LLP encourages affected investors to consult with counsel promptly to ensure their rights are preserved.

Background on agilon health, Inc.

agilon health, Inc. operates as a healthcare services company focused on partnering with primary care physicians to provide value-based care for senior patients. The Company’s model is designed to empower physicians with tools, technology, and administrative support while aligning incentives toward improved patient outcomes.

In recent years, agilon health has experienced rapid expansion as value-based care models gained traction across the healthcare industry. However, the complaint alleges that despite public statements touting strong growth and sustainable margins, internal challenges may have undermined the Company’s financial outlook.

Alleged Misrepresentations and Market Reaction

According to the lawsuit, when agilon health disclosed certain adverse information to the market, the Company’s stock price declined sharply. Investors claim that these price drops were directly linked to the revelation of previously concealed operational and financial difficulties.

Market analysts reportedly reacted with concern, adjusting ratings and lowering price targets following the Company’s disclosures. Shareholders who purchased stock at allegedly inflated prices suffered significant losses when the stock value fell.

Role of Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP is a nationally recognized securities litigation firm with extensive experience representing investors in complex class action cases. The firm has successfully recovered hundreds of millions of dollars for investors in cases involving corporate fraud, accounting irregularities, and misleading financial statements.

By issuing this reminder notice, the firm seeks to ensure that agilon health investors are aware of their rights and the impending March 2, 2026 deadline. The firm emphasizes that investors are not required to serve as lead plaintiff to participate in any potential recovery.

What Does Serving as Lead Plaintiff Mean?

The lead plaintiff is responsible for representing the interests of all class members. This includes:

• Selecting and retaining counsel;
• Providing input on litigation strategy;
• Reviewing settlement proposals;
• Participating in discovery when necessary.

While serving as lead plaintiff involves certain responsibilities, it does not typically require extensive day-to-day involvement.

Understanding Securities Class Actions

Securities class action lawsuits are designed to protect investors from corporate misconduct that violates federal securities laws. When companies allegedly provide false or misleading information, investors may make decisions based on inaccurate data. If the truth later emerges and stock prices fall, shareholders can suffer substantial financial harm.

Class actions allow multiple investors to consolidate their claims into a single lawsuit, promoting efficiency and ensuring consistent legal outcomes. Courts oversee the process to protect the interests of all class members.

Common Elements of a Securities Fraud Case

To succeed in a securities fraud case, plaintiffs generally must prove:

• A material misrepresentation or omission;
• Scienter, or intent to deceive or reckless disregard for the truth;
• A connection with the purchase or sale of securities;
• Reliance by investors;
• Economic loss;
• Loss causation.

The agilon health lawsuit will proceed through various procedural stages, including motions to dismiss, discovery, and potentially trial or settlement negotiations.

Potential Outcomes for Investors

If the lawsuit is successful—whether through settlement or court judgment—eligible investors may receive compensation for their losses. However, there is no guarantee of recovery, and the litigation process can take time.

Investors should carefully monitor developments in the case and remain informed about deadlines and procedural milestones.

Why Timely Action Matters

Missing the March 2, 2026 deadline could limit an investor’s ability to seek appointment as lead plaintiff. Although class members who do not seek lead plaintiff status may still participate, acting promptly ensures that investors retain full control over their legal options.

Faruqi & Faruqi LLP advises investors to gather relevant documentation, including trade confirmations and brokerage statements, when consulting with counsel.

Investor Rights and Responsibilities

Investors have important rights under federal securities laws, including the right to pursue claims against companies that allegedly engage in fraudulent conduct. At the same time, investors should exercise due diligence by staying informed and reviewing disclosures carefully.

Participation in a class action lawsuit typically does not require upfront payment of legal fees. Most securities class actions are handled on a contingency basis, meaning attorneys’ fees are only paid if there is a recovery.

Steps Investors Should Consider

1. Review Your Investment Records: Determine whether you purchased agilon health securities during the class period.
2. Assess Your Losses: Calculate any financial harm suffered.
3. Consult with Counsel: Seek guidance from an experienced securities litigation attorney.
4. Meet the Deadline: File any necessary motions by March 2, 2026 if seeking lead plaintiff status.

Market Transparency and Corporate Accountability

Securities litigation plays a critical role in promoting transparency and accountability in the financial markets. When companies are held responsible for misleading statements, it reinforces investor confidence and strengthens market integrity.

The agilon health case underscores the importance of accurate financial reporting and candid communication with shareholders. Investors rely heavily on corporate disclosures when making decisions about buying, holding, or selling securities.

Broader Implications for the Healthcare Sector

The healthcare industry has experienced rapid transformation in recent years, particularly in value-based care models. Companies operating in this space face complex reimbursement structures, regulatory oversight, and cost pressures.

Allegations of financial misrepresentation can have ripple effects throughout the sector, influencing investor sentiment and market valuations. The outcome of this case may be closely watched by analysts and industry participants alike.

Conclusion: Act Before March 2, 2026

As the March 2, 2026 deadline approaches, agilon health investors are urged to take proactive steps to protect their rights. Faruqi & Faruqi, LLP continues to investigate the claims and encourages affected shareholders to explore their legal options.

Investors who believe they suffered losses due to alleged securities law violations should act promptly. Whether seeking appointment as lead plaintiff or simply remaining part of the class, understanding the process and meeting key deadlines are essential.

The coming months will determine how the litigation unfolds. For now, the most important message for agilon health investors is clear: the deadline to seek lead plaintiff status is March 2, 2026.

As financial markets evolve and corporate transparency remains paramount, legal mechanisms such as securities class actions serve as vital tools for investor protection. By staying informed and acting within the prescribed timeframe, investors can ensure their interests are represented in the pursuit of accountability and potential recovery.

#AGLInvestorAlert #agilonhealth #SecuritiesClassAction #InvestorDeadline #SlimScan #GrowthStocks #CANSLIM